A carregar...
Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies
BACKGROUND: Recently, brentuximab vedotin has become a promising therapeutic approach for CD30-positive hematological malignancies, but its role in other relapsed or refractory malignant lymphoma needs to be proven. Brentuximab vedotin was demonstrated effective, but no study has summarized the conc...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4408955/ https://ncbi.nlm.nih.gov/pubmed/25945039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S83592 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|